Susanna Scarpa

Pubblicazioni

Titolo Pubblicato in Anno
Anthracycline-free neoadjuvant chemotherapy ensures higher rates of pathologic complete response in breast cancer CLINICAL BREAST CANCER 2017
Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer THE INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS 2017
Thyroid hormone regulates fibronectin expression through the activation of the hypoxia inducible factor 1 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 2017
Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells ONCOLOGY LETTERS 2017
Nodal and cutaneous Kaposi's sarcoma GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA 2016
Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation TUMOR BIOLOGY 2016
Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients TUMOR BIOLOGY 2016
The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells INVESTIGATIONAL NEW DRUGS 2016
Long-lasting stent placement in an elderly advanced ovarian cancer patient ONCOLOGY RESEARCH AND TREATMENT 2016
Metronomic chemotherapy preserves quality of life ensuring efficacy in elderly advanced non small cell lung cancer patients INTERNATIONAL JOURNAL OF CANCER AND CLINICAL RESEARCH 2016
Novel schedule for treatment of inflammatory breast cancer OPEN JOURNAL OF CLINICAL & MEDICAL CASE REPORTS 2016
Synchronous primary papillary breast cancer, medullary thyroid carcinoma and neuroendocrine tumor in postmenopausal woman JOURNAL OF CASE REPORTS IN ONCOLOGY AND THERAPY 2016
On and off metronomic oral vinorelbine in elderly women with advanced breast cancer TUMORI 2015
BCM-95 and 2-hydroxypropyl b-cyclodextrin reverse autophagy dysfunction and deplete stored lipids in Sap-C deficient fibroblasts. HUMAN MOLECULAR GENETICS 2015
Taxane induced neuropathy in patients affected by breast cancer: literature review CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 2015
Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy? CLINICAL SCIENCE 2015
Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review CANCER CHEMOTHERAPY AND PHARMACOLOGY 2015
Are we ready to change clinical practice after the 'soft and text' results? FUTURE ONCOLOGY 2015
Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2015
Molecular alterations chemoresistance-related in ovarian cancer patients and related target therapies Handbook on Ovarian Cancer 2015

ERC

  • LS4_12

Interessi di ricerca

Attualmente testiamo l'attività anti-tumorale di composti di nuova sintesi su vari tipi di tumori umani in vitro. Ne valutiamo gli effetti su molte proprietà del fenotipo maligno, quali il controllo dei checkpoints del ciclo cellulare, l'induzione di apoptosi, il controllo sulle capacità di invasione locale, quali la transizione epitelio mesenchimale, la produzione di enzimi proteolitici e la invasione della matrice extracellulare. 

Keywords

antitumor agents
apoptosis
extracellular matrix remodeling
tubulin inhibitors

Progetti di Ricerca

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma